Acquired severe aplastic anemia (SAA) is a rare hematologic disease associated with
significant morbidity and mortality. Immune destruction of hemopoietic stem cells plays an …

Survival in severe aplastic anemia (SAA) has markedly improved in the past 4 decades
because of advances in hematopoietic stem cell transplantation, immunosuppressive …

Background A single-group, phase 1–2 study indicated that eltrombopag improved the
efficacy of standard immunosuppressive therapy that entailed horse antithymocyte globulin …

Background Acquired aplastic anemia results from immune-mediated destruction of bone
marrow. Immunosuppressive therapies are effective, but reduced numbers of residual stem …

1The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth,
2Northern Genetics Service, Newcastle upon Tyne, 3St Bartholomew's Hospital, Barts …

Background In patients with acquired aplastic anemia, destruction of hematopoietic cells by
the immune system leads to pancytopenia. Patients have a response to immunosuppressive …

Pancytopenia with hypocellular bone marrow is the hallmark of aplastic anaemia (AA) and
the diagnosis is confirmed after careful evaluation, following exclusion of alternate diagnosis …

The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid
disorders with a highly variable disease course. Diagnostic criteria to better stratify patients …

Patients with severe aplastic anemia (SAA) are either treated with bone marrow transplant
(BMT) or immunosuppression (IST) depending on their age, comorbidities, and available …

Background Severe aplastic anemia, which is characterized by immune-mediated bone
marrow hypoplasia and pancytopenia, can be treated effectively with immunosuppressive …